证监会：拟降费！重要指数调整，今起生效……盘前重要消息一览

Key Points - The core viewpoint of the article highlights significant developments in the financial and investment sectors, including regulatory changes, market adjustments, and company-specific news that could impact investment strategies and opportunities. Group 1: Regulatory and Economic Developments - The China Securities Regulatory Commission (CSRC) has released revised regulations on public fund sales fees, marking the final step in a phased fee reform, which is expected to benefit investors by over 50 billion yuan annually [4] - The People's Bank of China reported that as of the end of August, the country's gold reserves increased to 74.02 million ounces, marking the tenth consecutive month of gold accumulation [4] - China's foreign exchange reserves rose to 33,222 billion USD by the end of August, an increase of 29.9 billion USD from the previous month, reflecting a growth rate of 0.91% [4] Group 2: Market Adjustments and Company News - The Hang Seng Index will see the addition of China Telecom, JD Logistics, and Pop Mart as component stocks, effective September 8, increasing the total number of component stocks from 85 to 88 [4] - The U.S. non-farm payrolls increased by 22,000 in August, significantly below market expectations of 75,000, indicating potential economic slowdown [5] - Shenzhen has introduced new housing market policies aimed at optimizing housing purchase restrictions and personal housing credit policies [5] Group 3: Company-Specific Developments - Zhaoxin Co. reported that its largest shareholder did not trade shares during periods of unusual stock price fluctuations [8] - Tianji Co. is gaining attention in the solid-state battery sector, with its subsidiary obtaining patents for lithium sulfide materials [8] - Sunfar Group sold 166,400 pigs in August, generating sales revenue of 285 million yuan [8] - Tianbang Foods reported sales of 529,700 pigs in August, with a revenue of 621 million yuan [8] - ST Pawa received a notice from the CSRC regarding an investigation [8] - Junshi Biosciences achieved primary research endpoints in a Phase III clinical trial for a treatment of moderate to severe plaque psoriasis [8]